Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)Susan Bal, Jesús G. Berdeja, Myo Htut et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior RegimensSusan Bal, Omar Nadeem, Myo Htut et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)Safiyyah Ziyad, Jesús G. Berdeja, Shari M. Kaiser et al.|Blood|2025Cited by 0
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)Susan Bal, Sham Mailankody, Ziyan Guo et al.|Blood|2025Cited by 0